SOURCE: MDRNA, Inc.

MDRNA, Inc.

December 01, 2009 08:00 ET

MDRNA, Inc. Presents to International Webinar Audience on Innovations in Oncology Drug Discovery, Development & Delivery

Presentation Highlights Versatility and Breadth of Its Proprietary siRNA Drug Discovery and Delivery Platform

BOTHELL, WA--(Marketwire - December 1, 2009) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced a webinar presentation related to its RNAi oncology programs at the Innovations in Oncology Drug Discovery, Development and Delivery Webinar Series to be presented on December 1, at 1:00 pm EST. Roger Adami, Ph.D., Director, Molecular Pharmaceutics at MDRNA will present preclinical data demonstrating anti-tumor activity in an orthotopic model of liver cancer and an orthotopic model of bladder cancer.

The presentation by Dr. Adami titled, "Versatile Platform for siRNA Delivery Using Novel Amino Acid Derivatives," describes MDRNA's siRNA delivery systems, based on the DiLA2 amino acid platform and its proprietary siRNA construct, termed UsiRNA. Dr. Adami will present data on MRNA-046, a UsiRNA targeting human survivin formulated in the DiLA2 delivery system. MRNA-046 demonstrated a 65% decrease in tumor weight in a rodent model of liver cancer compared to negative controls. This decrease in tumor weight was similar to Avastin treated mice which served as the positive control. The same compound, MRNA-046, achieved up to a 90% mRNA target knockdown in a mouse model of bladder cancer. The effects of MRNA-046 persisted for the duration of the three week study, and the level of survivin mRNA knockdown was associated with a significant reduction in tumor growth as measured by fluorescence from the luciferase-expressing tumor cells.

For additional information regarding the Webinar please go to: http://www.nextlevelpharma.com/events/view/innovations_in_oncology_drug_discovery_ development_delivery

About UsiRNAs and Unlocked Nucleobase Analogs

A UsiRNA is a duplex siRNA containing at least one Unlocked Nucleobase Analog (UNA). In a UsiRNA, UNAs are non-nucleotide monomers and synthesized much like RNA in the construction of a double-stranded oligonucelotide for use as an RNAi-based therapeutic. In the case of the UsiRNA, UNA is substituted for specific nucleotides in both the guide and passenger strands. UsiRNAs are fully recognized by the cellular RNAi machinery, as demonstrated by their potent activity. MDRNA has also shown that substitution of UNA for specific RNA increases stability to nucleases, substantially reduces cytokine induction, and reduces passenger and guide strand-mediated offtarget effects. The high potency, and improved drug-like properties, associated with UsiRNAs provide the potential to greatly enhance RNAi-based therapeutics.

About the DiLA2 Delivery Platform

The DiLA2 Delivery Platform is MDRNA's proprietary platform for creating novel liposomal delivery systems based on di-alkylated amino acids (DiLA2). The DiLA2 Platform enables MDRNA to tailor the charge, linker length, and acyl chain characteristics to improve delivery of the liposomes to target tissues of interest. In vivo studies have demonstrated effective delivery in models of metabolic disease, cancer, and other diseases. DiLA2-based liposomes are well tolerated for repeat dose, and systemic and local administration. MDRNA is also utilizing condensing peptides to form peptide-siRNA nanoparticles to further increase the delivery efficiency of its DiLA2 delivery systems. In addition, the platform is designed to permit attachment of peptides and other targeting molecules for delivery to a variety of tissues, and thus provide for a diverse therapeutic portfolio.

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in oncology. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.

MDRNA Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA to obtain additional funding; (ii) the ability of MDRNA to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contact Information